反応 #59759

反応方程式

DMF

4′-[5-(Chloromethyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide

4′-[5-(chloromethyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide

Intermediate 45

4′-[5-(chloromethyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide

potassium iodide

thiomorpholine

→

N-Cyclopropyl-6-methyl-4′-[5-(thiomorpholin-4-ylmethyl)-1,3,4-oxadiazol-2-yl]-1,1′-biphenyl-3-carboxamide

反応条件

後処理

1. 1
   その他The solvents were evaporated under vacuum
2. 2
   その他the residue purified by bond-elut (silica)
3. 3
   洗浄eluting with an ethyl acetate/cyclohexane gradient
4. 4
   その他After evaporation of the solvent this gave N-cyclopropyl-6-methyl-4′-[5-(thiomorpholin-4-ylmethyl)-1,3,4-oxadiazol-2-yl]-1,1′-biphenyl-3-carboxamide

実験手順

4′-[5-(Chloromethyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide (Intermediate 45) (37 mg) and potassium iodide (5 mg) were mixed in thiomorpholine (2 ml) and DMF (2 ml) and the reaction stirred at room temperature for 18 hours. The solvents were evaporated under vacuum and the residue purified by bond-elut (silica), eluting with an ethyl acetate/cyclohexane gradient. After evaporation of the solvent this gave N-cyclopropyl-6-methyl-4′-[5-(thiomorpholin-4-ylmethyl)-1,3,4-oxadiazol-2-yl]-1,1′-biphenyl-3-carboxamide.

出典